OncoMatch/Esophageal Cancer/HER2 (ERBB2)
Esophageal CancerHER2 (ERBB2) Clinical Trials
HER2 overexpression or amplification occurs in approximately 15–20% of esophageal and gastroesophageal junction (GEJ) adenocarcinomas; it is uncommon in esophageal squamous cell carcinoma. Trastuzumab added to platinum/fluoropyrimidine chemotherapy is first-line standard for HER2-positive GEJ/gastric adenocarcinoma; trastuzumab deruxtecan (T-DXd) is approved in the second-line setting. Trials investigate T-DXd first-line combinations and novel HER2-directed ADCs specifically for HER2-positive esophageal and GEJ adenocarcinoma.
Top recruiting HER2 (ERBB2) Esophageal Cancer trials
Ranked by phase and US site count. See all 24 trials matched to your profile →
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
RemeGen Co., Ltd.
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Boehringer Ingelheim
Browse other molecular targets with active Esophageal Cancer trials.